首页> 外国专利> Improved formulations of levosimendan for intravenous administration as infusion or injection and of concentrate for infusion

Improved formulations of levosimendan for intravenous administration as infusion or injection and of concentrate for infusion

机译:左西孟旦用于静脉内输注或注射的改良制剂以及用于输注的浓缩液

摘要

The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan is present in a solubilized form. The formulations have therapeutically and commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solution after reconstitution in water or an aqueous solvent. Levosimendan or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.
机译:本发明涉及用于药物用途的左西孟旦的改进制剂,特别是用于输注或注射的静脉内给药以及输注浓缩物。因此,本发明涉及包含左西孟旦的药物组合物,其中左西孟旦以增溶形式存在。所述制剂具有治疗和商业上有用的左西孟旦浓度。本发明的溶液在生理pH(pH 7.4)下具有增强的能力,并且特别可用作输注或注射溶液或输注浓缩物。还可以将本发明的组合物喷雾干燥或冻干以获得非常稳定的干燥粉末,并且该粉末在水或水性溶剂中重构后形成原始溶液。左西孟旦或(-)-[[4-(1,4,5,6-四氢-4-甲基-6-氧代-3-吡啶并基-苯基)苯基]肼基]丙烷腈可用于治疗充血性心力衰竭。

著录项

  • 公开/公告号DK3370693T3

    专利类型

  • 公开/公告日2020-03-23

    原文格式PDF

  • 申请/专利权人 CARINOPHARM GMBH;

    申请/专利号DK20160790403T

  • 发明设计人 WEILAND ANDREA;

    申请日2016-11-04

  • 分类号A61K9/08;A61K9/19;A61K31/50;A61P9/04;

  • 国家 DK

  • 入库时间 2022-08-21 11:17:46

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号